Evaluating Serum Heat Shock Protein Levels as Novel Biomarkers for Atrial Fibrillation
<b>Background:</b> Staging of atrial fibrillation (AF) is essential to understanding disease progression and the accompanied increase in therapy failure. Blood-based heat shock protein (HSP) levels may enable staging of AF and the identification of patients with higher risk for AF recurr...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-09-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/9/9/2105 |
| _version_ | 1827706134758162432 |
|---|---|
| author | Denise M. S. van Marion Eva A. H. Lanters Kennedy S. Ramos Jin Li Marit Wiersma Luciënne Baks-te Bulte Agnes J. Q. M. Muskens Eric Boersma Natasja M. S. de Groot Bianca J. J. M. Brundel |
| author_facet | Denise M. S. van Marion Eva A. H. Lanters Kennedy S. Ramos Jin Li Marit Wiersma Luciënne Baks-te Bulte Agnes J. Q. M. Muskens Eric Boersma Natasja M. S. de Groot Bianca J. J. M. Brundel |
| author_sort | Denise M. S. van Marion |
| collection | DOAJ |
| description | <b>Background:</b> Staging of atrial fibrillation (AF) is essential to understanding disease progression and the accompanied increase in therapy failure. Blood-based heat shock protein (HSP) levels may enable staging of AF and the identification of patients with higher risk for AF recurrence after treatment. <b>Objective:</b> This study evaluates the relationship between serum HSP levels, presence of AF, AF stage and AF recurrence following electrocardioversion (ECV) or pulmonary vein isolation (PVI). <b>Methods:</b> To determine HSP27, HSP70, cardiovascular (cv)HSP and HSP60 levels, serum samples were collected from control patients without AF and patients with paroxysmal atrial fibrillation (PAF), persistent (PeAF) and longstanding persistent (LSPeAF) AF, presenting for ECV or PVI, prior to intervention and at 3-, 6- and 12-months post-PVI. <b>Results:</b> The study population (<i>n</i> = 297) consisted of 98 control and 199 AF patients admitted for ECV (<i>n</i> = 98) or PVI (<i>n</i> = 101). HSP27, HSP70, cvHSP and HSP60 serum levels did not differ between patients without or with PAF, PeAF or LSPeAF. Additionally, baseline HSP levels did not correlate with AF recurrence after ECV or PVI. However, in AF patients with AF recurrence, HSP27 levels were significantly elevated post-PVI relative to baseline, compared to patients without recurrence. <b>Conclusions:</b> No association was observed between baseline HSP levels and the presence of AF, AF stage or AF recurrence. However, HSP27 levels were increased in serum samples of patients with AF recurrence within one year after PVI, suggesting that HSP27 levels may predict recurrence of AF after ablative therapy. |
| first_indexed | 2024-03-10T16:18:22Z |
| format | Article |
| id | doaj.art-315355a42ced4d5ebf984b89169584bf |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T16:18:22Z |
| publishDate | 2020-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-315355a42ced4d5ebf984b89169584bf2023-11-20T13:52:53ZengMDPI AGCells2073-44092020-09-0199210510.3390/cells9092105Evaluating Serum Heat Shock Protein Levels as Novel Biomarkers for Atrial FibrillationDenise M. S. van Marion0Eva A. H. Lanters1Kennedy S. Ramos2Jin Li3Marit Wiersma4Luciënne Baks-te Bulte5Agnes J. Q. M. Muskens6Eric Boersma7Natasja M. S. de Groot8Bianca J. J. M. Brundel9Department of Physiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije University, 1081HV Amsterdam, The NetherlandsDepartment of Cardiology, Erasmus MC, 3000CA Rotterdam, The NetherlandsDepartment of Physiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije University, 1081HV Amsterdam, The NetherlandsDepartment of Physiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije University, 1081HV Amsterdam, The NetherlandsDepartment of Physiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije University, 1081HV Amsterdam, The NetherlandsDepartment of Physiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije University, 1081HV Amsterdam, The NetherlandsDepartment of Cardiology, Erasmus MC, 3000CA Rotterdam, The NetherlandsDepartment of Cardiology, Erasmus MC, 3000CA Rotterdam, The NetherlandsDepartment of Cardiology, Erasmus MC, 3000CA Rotterdam, The NetherlandsDepartment of Physiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije University, 1081HV Amsterdam, The Netherlands<b>Background:</b> Staging of atrial fibrillation (AF) is essential to understanding disease progression and the accompanied increase in therapy failure. Blood-based heat shock protein (HSP) levels may enable staging of AF and the identification of patients with higher risk for AF recurrence after treatment. <b>Objective:</b> This study evaluates the relationship between serum HSP levels, presence of AF, AF stage and AF recurrence following electrocardioversion (ECV) or pulmonary vein isolation (PVI). <b>Methods:</b> To determine HSP27, HSP70, cardiovascular (cv)HSP and HSP60 levels, serum samples were collected from control patients without AF and patients with paroxysmal atrial fibrillation (PAF), persistent (PeAF) and longstanding persistent (LSPeAF) AF, presenting for ECV or PVI, prior to intervention and at 3-, 6- and 12-months post-PVI. <b>Results:</b> The study population (<i>n</i> = 297) consisted of 98 control and 199 AF patients admitted for ECV (<i>n</i> = 98) or PVI (<i>n</i> = 101). HSP27, HSP70, cvHSP and HSP60 serum levels did not differ between patients without or with PAF, PeAF or LSPeAF. Additionally, baseline HSP levels did not correlate with AF recurrence after ECV or PVI. However, in AF patients with AF recurrence, HSP27 levels were significantly elevated post-PVI relative to baseline, compared to patients without recurrence. <b>Conclusions:</b> No association was observed between baseline HSP levels and the presence of AF, AF stage or AF recurrence. However, HSP27 levels were increased in serum samples of patients with AF recurrence within one year after PVI, suggesting that HSP27 levels may predict recurrence of AF after ablative therapy.https://www.mdpi.com/2073-4409/9/9/2105atrial fibrillationheat shock proteinelectrical cardioversionpulmonary vein isolationbiomarkers |
| spellingShingle | Denise M. S. van Marion Eva A. H. Lanters Kennedy S. Ramos Jin Li Marit Wiersma Luciënne Baks-te Bulte Agnes J. Q. M. Muskens Eric Boersma Natasja M. S. de Groot Bianca J. J. M. Brundel Evaluating Serum Heat Shock Protein Levels as Novel Biomarkers for Atrial Fibrillation Cells atrial fibrillation heat shock protein electrical cardioversion pulmonary vein isolation biomarkers |
| title | Evaluating Serum Heat Shock Protein Levels as Novel Biomarkers for Atrial Fibrillation |
| title_full | Evaluating Serum Heat Shock Protein Levels as Novel Biomarkers for Atrial Fibrillation |
| title_fullStr | Evaluating Serum Heat Shock Protein Levels as Novel Biomarkers for Atrial Fibrillation |
| title_full_unstemmed | Evaluating Serum Heat Shock Protein Levels as Novel Biomarkers for Atrial Fibrillation |
| title_short | Evaluating Serum Heat Shock Protein Levels as Novel Biomarkers for Atrial Fibrillation |
| title_sort | evaluating serum heat shock protein levels as novel biomarkers for atrial fibrillation |
| topic | atrial fibrillation heat shock protein electrical cardioversion pulmonary vein isolation biomarkers |
| url | https://www.mdpi.com/2073-4409/9/9/2105 |
| work_keys_str_mv | AT denisemsvanmarion evaluatingserumheatshockproteinlevelsasnovelbiomarkersforatrialfibrillation AT evaahlanters evaluatingserumheatshockproteinlevelsasnovelbiomarkersforatrialfibrillation AT kennedysramos evaluatingserumheatshockproteinlevelsasnovelbiomarkersforatrialfibrillation AT jinli evaluatingserumheatshockproteinlevelsasnovelbiomarkersforatrialfibrillation AT maritwiersma evaluatingserumheatshockproteinlevelsasnovelbiomarkersforatrialfibrillation AT luciennebakstebulte evaluatingserumheatshockproteinlevelsasnovelbiomarkersforatrialfibrillation AT agnesjqmmuskens evaluatingserumheatshockproteinlevelsasnovelbiomarkersforatrialfibrillation AT ericboersma evaluatingserumheatshockproteinlevelsasnovelbiomarkersforatrialfibrillation AT natasjamsdegroot evaluatingserumheatshockproteinlevelsasnovelbiomarkersforatrialfibrillation AT biancajjmbrundel evaluatingserumheatshockproteinlevelsasnovelbiomarkersforatrialfibrillation |